Noxopharm (Noxopharm) EV-to-EBIT : -0.60 (As of May. 14, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Noxopharm EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Noxopharm's Enterprise Value is $4.83 Mil. Noxopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.09 Mil. Therefore, Noxopharm's EV-to-EBIT for today is -0.60.

The historical rank and industry rank for Noxopharm's EV-to-EBIT or its related term are showing as below:

NOXOF' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.38 Med: 0 Max: 83.32
Current: -0.61

During the past 7 years, the highest EV-to-EBIT of Noxopharm was 83.32. The lowest was -20.38. And the median was 0.00.

NOXOF's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 9.44 vs NOXOF: -0.61

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Noxopharm's Enterprise Value for the quarter that ended in Dec. 2023 was $5.31 Mil. Noxopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.09 Mil. Noxopharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -152.34%.

Noxopharm EV-to-EBIT Historical Data

The historical data trend for Noxopharm's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm EV-to-EBIT Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

Get a 7-Day Free Trial

-4.86

13.84

-22.27

-2.32

-0.64

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial										-	-2.32	-	-0.64	-

Competitive Comparison of Noxopharm's EV-to-EBIT

For the Biotechnology subindustry, Noxopharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Noxopharm's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noxopharm's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Noxopharm's EV-to-EBIT falls into.

Noxopharm EV-to-EBIT Calculation

Noxopharm's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	4.833	/	-8.094
	=	-0.60

Noxopharm's current Enterprise Value is $4.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Noxopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.09 Mil.

Noxopharm (OTCPK:NOXOF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Noxopharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-8.094	/	5.31314
	=	-152.34 %

Noxopharm's Enterprise Value for the quarter that ended in Dec. 2023 was $5.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Noxopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.09 Mil.

Noxopharm EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Noxopharm's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (Noxopharm) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (OTCPK:NOXOF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

NOX:Australia

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.